🤔 To switch or not to switch, that is the question…

… we can help you answer!

The switch of a drug from prescription-only (Rx) to over-the-counter (OTC) status opens up new and innovative opportunities for pharmaceutical manufacturers to position and market their products. 💊

Although Austria is still relatively far behind in terms of the availability of OTC preparations, our medical writers have taken up the subject with passion and have developed over the years into impressive switch experts!

💡 It all started with the first Switch Conference of the IGEPHA in Austria 2018, where the potential and possibilities of switches on the Austrian pharmaceutical market were demonstrated.

We did not wait long and in the same year wrote 4 Switch applications for Austria – all with success! 🎉

Since then, a lot has happened: We have been involved in over 20 Rx-to-OTC projects in the last 5 years, of which we wrote the Switch Argumentation ourselves.

Our biggest highlight so far is definitely the successful OTC switch of a “first-in-class” product in Austria, in which we have been involved both in advisory and lead roles. We are particularly proud of this! 💪

Currently, we are once again able to participate in exciting Rx-to-OTC projects – we are currently working on switch applications from 2 customers in a total of 10 European countries.

So if you are wondering “to switch or not to switch”, we are happy to help you! 😊